Regeneron, Sanofi expand antibody alliance with USD 1 billion upfront payment

• Regeneron expanded its immunology alliance with Sanofi to co-develop and co-commercialize four next-generation, long-acting antibodies.
• Sanofi will pay USD 1 billion upfront; Regeneron can earn up to USD 7 billion in development, regulatory, commercial milestones.
• Companies will split global development and commercialization costs 50:50; future profits from the new products will also be shared 50:50.
• Regeneron will lead R&D; Sanofi will lead global commercialization; existing Dupixent profit-sharing terms remain unchanged.
• REGN20423 is in Phase 1 for atopic dermatitis; three other programs are expected to enter clinical studies in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010100PRIMZONEFULLFEED9837599) on October 01, 2026, and is solely responsible for the information contained therein.